



Published in final edited form as:

*Support Care Cancer*. 2019 January ; 27(1): 147–156. doi:10.1007/s00520-018-4299-6.

## Health Care Improvement and Survivorship Priorities of Colorectal Cancer Survivors: Findings from the PORTAL Colorectal Cancer Cohort Survey

Carmit McMullen, PhD<sup>1</sup>, Joanna Bulkley, PhD<sup>1</sup>, Douglas A. Corley, MD, PhD<sup>2</sup>, Sarah Madrid, MA<sup>3</sup>, Anjelica Q. Davis, MPPA<sup>4</sup>, Rose Hesselbrock, BA<sup>5,6</sup>, Florence Kurtilla, MS<sup>4,5</sup>, Charles K. Anderson, MDiv<sup>5</sup>, David Arterburn, MD, MPH<sup>6</sup>, Carol P. Somkin, PhD<sup>2</sup>, Pamala A. Pawloski, PharmD<sup>7</sup>, Nirupa R. Ghai, PhD<sup>8</sup>, Heather Spencer Feigelson, PhD, MPH<sup>3</sup>

<sup>1</sup>Center for Health Research, Kaiser Permanente Northwest

<sup>2</sup>Division of Research, Kaiser Permanente Northern California

<sup>3</sup>Institute for Health Research, Kaiser Permanente Colorado

<sup>4</sup>Fight Colorectal Cancer (Fight CRC), Springfield, MO

<sup>5</sup>PORTAL Patient Engagement Council

<sup>6</sup>Kaiser Permanente Washington Research Institute, Seattle, WA

<sup>7</sup>HealthPartners Institute, Minneapolis, MN

<sup>8</sup>Department of Research & Evaluation, Kaiser Permanente Southern California

### Abstract

**Purpose:** Few population-level surveys have explored patient-centered priorities for improving colorectal cancer survivors' care. Working with patients, we designed a survey to identify care improvement and survivorship priorities.

**Methods:** We surveyed a random sample of 4,000 patients from a retrospective, population-based cohort of colorectal cancer survivors diagnosed during 2010–2014. The survey included two multiple response questions: “What would you have changed about your cancer diagnosis and treatment experience?” and “What are your biggest health or lifestyle concerns (other than having

---

**Corresponding Author:** Carmit K McMullen, PhD, The Center for Health Research - Kaiser Permanente Northwest, 3800 N. Interstate Ave., Portland, OR 97227, Carmit.Mcmullen@kpchr.org, Phone: 503-335-6381, Fax: 503-335-2424.

Author Contributions:

Carmit McMullen, PhD: Design, analysis, interpretation, writing, and final approval.

Joanna Bulkley, PhD: Analysis, interpretation, writing, and final approval.

Douglas A. Corley, MD, PhD: Design, analysis, interpretation, writing, and final approval.

Sarah Madrid, MA: Design, acquisition, writing, and final approval.

Anjelica Q. Davis, MPPA: Design, interpretation, writing, and final approval.

Rose Hesselbrock, BA: Design, interpretation, writing, and final approval.

Florence Kurtilla, MS: Design, interpretation, writing, and final approval.

Charles K. Anderson, MDiv: Design, interpretation, writing, and final approval.

David Arterburn, MD, MPH: Design, interpretation, writing, and final approval.

Carol P. Somkin, PhD: Design, interpretation, writing, and final approval.

Pamala A. Pawloski, PharmD: Design, interpretation, writing, and final approval.

Nirupa R. Ghai, PhD: Interpretation, writing, and final approval.

Heather Spencer Feigelson, PhD, MPH: Design, acquisition, analysis, interpretation, writing, and final approval.

cancer) since being diagnosed?” Multivariable regression identified characteristics associated with endorsement of health care experience and survivorship concerns.

**Results:** Survey response rate was 50.2% (2,000/3,986). 53% reported at least one unmet need, most commonly for more information about life after treatment (26.7%). Survivors of rectal cancer reported more needs than respondents with colon cancer; persons of color reported more needs than non-Hispanic whites; individuals without high school diplomas reported more needs than individuals with more education. Fear of recurrence was the most common health/lifestyle concern (58.9%). Respondents under age 65 reported nearly all health/lifestyle concerns more often than respondents over age 74. Rectal cancer survivors reported more concerns about activity limitation, changes and body function and appearance than colon cancer survivors. Persons of color were more likely to report financial concerns than non-Hispanic whites.

**Conclusions:** The greatest needs for intervention are among survivors of rectal cancer, survivors of minority racial/ethnic background, and survivors of younger age. Survivors with low educational attainment, and those with higher stage disease could also benefit.

### Keywords

Colorectal cancer; cancer survivors; health disparities; care improvement; survey

---

### Introduction

Few population-level surveys in the United States have elicited patient-reported experiences of care[1]. Cancer survivors report considerable unmet informational needs relating to health and health care, pointing to the need for interventions to empower patients to be well-informed during cancer treatment and survivorship[2]. A 2008 study of survivors of many cancer types, surveyed 2–5 years after diagnosis, found prevalent unmet information needs relating to tests and treatments, health promotion, side effects and symptoms, personal relationships, and emotional issues. Younger age, non-White race/ethnicity, a greater number of health problems, and reported problems with the quality of cancer care were associated with more unmet informational needs[3]. A follow-up study found that informational needs among cancer patients persist years after cancer diagnosis, with concerning disparities among minorities and patients diagnosed at a younger age[4].

A national survey of US cancer survivors found that 19% of colorectal cancer (CRC) survivors reported unmet needs relating to education and information and 17% reported unmet needs relating to systems of care[5]. In a UK survey of CRC survivors, negative experiences of care most often related to lack of post-treatment care and insufficient information concerning self-management (11% and 8% of negative experiences, respectively)[6].

Previous surveys have been limited by sparse information about respondents’ cancer site, stage at diagnosis, and other characteristics that would help identify groups who would most benefit from interventions. The purpose of this study was to identify health care improvement and survivorship priorities among a large, diverse and well-characterized

cohort of CRC survivors in the US and to identify subgroups who could benefit most from intervention.

## Materials & Methods

### Study setting and population

The study population was derived from the Patient Outcomes Research to Advance Learning (PORTAL) Network, funded by the Patient Centered Outcomes Research Institute. PORTAL includes 6 health systems and 9 research centers affiliated with those systems. Together, PORTAL health systems provide care for approximately 13 million members, or 1 of every 25 people in the United States[7,8]. This study was approved by the Institutional Review Board (IRB) of Kaiser Permanente Colorado (KPCO). After review and approval, all other participating health plans ceded oversight to the KPCO IRB.

A retrospective cohort of CRC survivors was developed from the population and included all cases diagnosed between 1/1/2010 and 12/31/2014 at one of 6 health care systems: Group Health Cooperative in Seattle, WA (now Kaiser Permanente Washington); HealthPartners in Minneapolis, MN; and Kaiser Permanente (KP) health plans in Colorado, Southern California, Northern California, and Oregon/southwest Washington. A random sample of 4,000 people from the cohort were invited to complete a survey, administered by multiple modalities including paper, online, and interactive voice response. Details of the cohort and sampling frame are provided elsewhere[9].

### Patient engagement

Survey administration modalities, questions, and response categories were developed in partnership with patient advisors, and a representative from PORTAL's CRC nonprofit advocacy partner, Fight Colorectal Cancer ([fightcolorectalcancer.org](http://fightcolorectalcancer.org)). Patient partners reviewed preliminary results, participated in the interpretation of survey results, and have co-authored this manuscript (AD, RH, FK, CA).

### Measures

**Administrative data:** Tumor, clinical, and demographic characteristics were drawn from the Health Care Systems Research Network's Virtual Data Warehouse (VDW), which includes standardized variables derived from electronic health records and administrative databases at each participating health care system[10–13]. We used tumor registry tables to define CRC (ICD-O-3 codes: C180, C182-C189, C199, C209) and to obtain information about cancer stage at diagnosis, and first course of cancer treatment (surgery, chemotherapy, radiotherapy). Vital status, birthdate, race/ethnicity, gender, and language preference (English or Spanish) were extracted from other tables in the VDW.

**Patient-reported data:** The 17-item survey included 2 questions about unmet needs and priorities. The first asked about health care experience: "If you could, what would you have changed about your cancer diagnosis and treatment experience?" Respondents were instructed to select all categories that applied to them, from a list including: better information or understanding about 1) treatment options; 2) treatment side effects; 3)

recovery time; 4) life after treatment; or 5) would not have changed anything. Participants could also select “other” and were given space to include a comment. The second question asked: “What are your biggest health or lifestyle concerns (other than having cancer) since being diagnosed?” Respondents were instructed to select all categories that applied to them, from a list including: 1) limitations on activity; 2) inability to sleep/lack of sleep; 3) changes to weight; changes to diet; 4) changes to my body functions, such as in frequency of bowel movements; 5) changes from surgery that I can see, such as a colostomy, scars, etc.; 6) financial issues; and 7) possibility of cancer recurrence. This question also offered an “other” category, followed by a space for comments. Patients were asked to report their highest education level.

## Analysis

We analyzed the relationship between endorsement (yes/no) of each unmet health care need or health/lifestyle concern and 6 demographic and clinical characteristics (age, gender, race/ethnicity, education, cancer site, cancer stage). We explored subgroup differences in satisfaction with cancer care experiences further by using a series of multivariable logistic regression models, with each cancer care experience as the outcome and the participant characteristics as predictors. To quantify the extent of unmet needs relating to health care experience, we created a count variable by summing the number of concerns reported (range: 0–4) and conducted linear regression analysis to identify demographic and clinical predictors of that variable. All models were adjusted for health plan, although we did not consider health plan as a predictor. Because very few responses included open-ended comments, we did not include these in the current analysis.

## Results

The response rate was 50.2% (2,000/3,986). We excluded 53 respondents who either denied a prior diagnosis of CRC (n=33) or because their tumor site (as coded by tumor registries) was not in the colon, rectosigmoid junction, or rectum (n=20). The average age of participants was 68.6 years (range = 17.0 to 99.2 years), 51.1% were male, 69.1% were non-Hispanic white, and 69.1% had at least some college education (Table 1). Colon cancer survivors were older than rectosigmoid or rectal cancer survivors ( $p < 0.001$ ). Rectal cancer survivors were more likely male than female ( $p < 0.001$ ). Respondents with colon, rectosigmoid, and rectal cancer did not differ by stage at diagnosis, and most respondents (84.5%) were diagnosed with cancer at stages 1–3.

### Opportunities for improving the cancer care experience

More than half (53%) of respondents were dissatisfied with at least one aspect of their cancer care, with 26.7% noting they would have liked to receive better information or understanding about life after treatment, 23.7% noting a lack of information about treatment side effects, 19.6% noting lack of information about recovery time, and 18.4% noting lack of information about treatment options. To better understand the prevalence of these concerns, Table 2 presents the unadjusted percentages of individuals endorsing each unmet need. Table 3 shows the results of the logistic regression analysis. All models were significant with Wald  $\chi^2$  (DF=20, N=1825) ranging from 56.4 to 94.1 (all  $p < 0.001$ ).

Age was associated with more need for information about treatment side effects (*Wald*  $\chi^2$  10.94,  $p=0.01$ ), recovery time (*Wald*  $\chi^2$  16.84,  $p<0.001$ ) and life after treatment (*Wald*  $\chi^2$  26.4,  $p<0.001$ ). Compared to survivors 75, those aged 50–64 were significantly more likely to report these needs (OR 1.64, 95% CI: 1.22, 2.21 for side effects; OR 1.82, 95% CI 1.33, 2.48 for recovery time; OR 2.03, 95% CI: 1.53, 2.69 for life after treatment). Gender was not a significant predictor in any of the models.

Respondents from minority race/ethnic groups were more likely than white and/or non-Hispanic respondents to report the need for more information or understanding about all aspects of care (OR 2.66, 95% CI: 2.00, 3.55 for treatment options; OR 1.44, 95% CI: 1.09, 1.92 for side effects; OR 1.79, 95% CI: 1.34, 2.39 for recovery time; and OR 1.63, 95% CI 1.24, 2.15 for life after treatment). Education level was a significant predictor of the need for information and understanding about treatment options (*Wald*  $\chi^2$  22.4,  $p<0.001$ ) and side effects (*Wald*  $\chi^2$  14.6,  $p=0.006$ ), and most of this difference was driven by the high level of need in our reference group, which included respondents with “some high school,” the lowest level of education (see Table 2).

Cancer site was a significant predictor of all of the unmet informational needs (treatment options *Wald*  $\chi^2$  6.0,  $p=0.05$ ; side effects *Wald*  $\chi^2$  22.2,  $p<0.001$ ; recovery time *Wald*  $\chi^2$  9.3,  $p=0.01$  and life after treatment *Wald*  $\chi^2$  24.8,  $p<0.001$ ). Compared to colon cancer survivors, survivors of rectal tumors were 1.43 to 1.85 times more likely to report unmet informational needs relating to all aspects of the cancer care experience. There was not a difference between survivors of colon and rectosigmoid cancer in the odds of endorsing unmet needs.

The odds of survivors reporting each type of unmet need generally increased by stage at diagnosis and the variable was a significant predictor of three of the four outcomes (treatment options *Wald*  $\chi^2$  11.6,  $p=0.02$ ; side effects *Wald*  $\chi^2$  22.1,  $p<0.001$ ; and life after treatment *Wald*  $\chi^2$  12.7,  $p=0.01$ ). Compared to survivors diagnosed at stage 1, survivors diagnosed at stage 3 were 1.5 to 1.9 times more likely to report these unmet needs. Survivors diagnosed at stage 4 were twice as likely to report unmet needs for better understanding of treatment options and side effects, compared to survivors diagnosed at stage 1. Survivors diagnosed at stage 4 did not differ from those diagnosed at stage 1 regarding information on life after treatment.

Figure 1 shows the adjusted mean number of unmet needs by patient characteristics. The overall model was significant and accounted for 6.8% of the variance ( $F=6.6$ ,  $p<0.001$ ). Five of the independent variables contributed significantly to the prediction of number of unmet information needs. After accounting for the variance explained by the other variables, respondents ages 50–65 reported significantly more unmet needs than those 75 ( $t=4.74$ ,  $p<0.001$ ). Participants who were Hispanic and/or from racial groups other than white reported more unmet needs than non-Hispanic whites ( $t=5.52$ ,  $p<0.001$ ); and individuals who had not graduated high school reported a greater number of unmet needs than individuals with more education (all  $t$  scores  $<-2.83$ , all  $p<0.005$ ). Respondents diagnosed with stage 2 ( $t=2.13$ ,  $p=0.033$ ), 3 ( $t=3.54$ ,  $p<0.001$ ), and 4 ( $t=2.34$ ,  $p=0.019$ ) cancer all had

more needs than respondents diagnosed at stage 1. Respondents who were survivors of rectal cancer reported more unmet needs than respondents with colon cancer ( $t=4.97$ ,  $p<0.001$ ).

### Health and lifestyle concerns during survivorship

The most common health and lifestyle concerns were fear of recurrence (58.9%) and changes in body or bowel function (40.9%). Other concerns were much less frequently endorsed (activity limitations, 26.8%; weight changes, 24.0%; sleep problems, 21.3%; visible changes from surgery, 16.6%; financial issues, 13.6%). Table 4 shows the unadjusted percentages of respondents who endorsed each health and lifestyle concern by subgroup.

We also examined the characteristics associated with each health and lifestyle concern using multivariable logistic regression (Table 5). All models were significant with Wald  $\chi^2$  (DF=20, N=1825) ranging from 46.3 to 113.4 (all  $p < 0.001$ ). Age was a significant predictor of all these concerns except limitations on activity (Wald  $\chi^2$  ranging from 46.3 to 113.4 (all  $p < 0.001$ ). Compared to survivors ages 75 and older, younger survivors (age <65 years) were more than twice as likely to report concerns about recurrence (OR=2.42, 95% CI: 1.53–3.83 for age < 50 and OR=2.19, 95% CI: 1.70–2.84 for ages 50–64). They were also more than three times as likely to report concerns about financial issues (OR=4.36, 95% CI: 2.51–7.57 for age < 50 and OR=3.13, 95% CI: 2.11–4.65 for ages 50–64). Compared to survivors ages 75 and above, the youngest survivors (under age 50) were more than twice as likely to report concerns about changes in their weight (OR=2.40, 95% CI 1.55–3.73) and diet (OR=2.95, 95% CI=1.86–4.66). We found no association with gender, with the exception of women having more concern with changes in weight than men (OR=1.53, 95% CI: 1.22–1.90). Survivors who were Hispanic and/or from a racial group other than white had nearly double the financial concerns of non-Hispanic whites (OR=1.85, 95% CI: 1.33–2.58).

Education level was a significant predictor of concern regarding sleep (Wald  $\chi^2$  13.32,  $p=0.01$ ), changes in body function (Wald  $\chi^2$  13.48,  $p=0.009$ ), visible changes caused by the surgery (Wald  $\chi^2$  12.45,  $p=0.01$ ), financial issues (Wald  $\chi^2$  15.52,  $p=0.004$ ), and recurrence (Wald  $\chi^2$  9.64,  $p=0.05$ ). Higher education was generally associated with fewer concerns about sleep, changes from surgery, and financial issues, but with more concerns about changes in body functions and cancer recurrence.

Cancer site was significantly related to limitations on activities (Wald  $\chi^2$  30.5,  $p<0.001$ ), changes in body function (Wald  $\chi^2$  58.94,  $p<0.001$ ), and visible changes from the surgery (Wald  $\chi^2$  52.35,  $p<0.001$ ). Compared to survivors with colon cancer, survivors with rectal cancer were almost two times more likely to have significant concerns about limitations on activity (OR=1.96, 95% CI: 1.52– 2.51) and almost three times more likely to be concerned about visible changes from surgery (OR=2.78, 95% CI: 2.10–3.68). Survivors of rectal and rectosigmoid cancer were more than twice as likely to express concern about changes in body functions compared to survivors of colon cancer (OR=2.36, 95% CI: 1.86–2.99).

Cancer stage was a significant predictor of concerns regarding limitations on activities (Wald  $\chi^2$  29.93,  $p<0.001$ ), sleep problems (Wald  $\chi^2$  10.11,  $p=0.04$ ), changes in body function (Wald  $\chi^2$  23.24,  $p<0.001$ ), visible changes caused by the surgery (Wald  $\chi^2$  16.27,  $p=0.003$ ),

and financial issues (*Wald*  $\chi^2$  23.56,  $p < 0.001$ ). Those diagnosed at stage 4 were significantly more likely to have concerns about limitations on activity (OR=2.70, 95% CI: 1.66–4.41), problems with sleep (OR=2.23, 95% CI: 1.34–3.73), and financial concerns (OR=3.29, 95% CI: 1.90–5.72) compared to those diagnosed at stage 1.

## Discussion & Conclusion

Most survivors endorsed opportunities to improve care during treatment. The most frequently identified priority was better communication about what to expect during life after cancer treatment. In this well-insured population, survivors with minority racial/ethnic background were consistently more likely than non-Hispanic whites to report unmet needs relating to their cancer care and to report financial concerns in survivorship. This suggests that, at least for CRC survivors, disparities in unmet informational needs[3,4] are not driven only by access to care. Culturally appropriate and tailored communication interventions to address diverse groups of survivors, which have shown promise in CRC screening[14], may also be effective in improving CRC treatment and survivorship care. It is worth noting that we are using standard categories for describing racial and ethnic subgroups the US population, which we do not consider a reflection of underlying biological differences.

Fear of recurrence has been reported as a major concern of cancer survivors[15], and our results confirm this. Recurrence was the most frequently noted survivorship concern in our cohort and was reported by a majority of respondents. Only age was shown to be a predictor of variability in this concern, with younger respondents expressing the concern most frequently.

Our results also highlight that rectal and colon cancer survivors have very different experiences of care and priorities for survivorship, and that rectosigmoid cancer patients' rating of priorities generally falls in between the two groups. This is likely due to the complexity of rectal cancer treatment and the lasting effects of surgery and radiation therapy on bowel function, whether or not patients have a permanent ostomy[16].

Other subgroups that could benefit from care improvement and survivorship interventions include: patients younger than 65, and to some extent, patients with later stage disease. For those under 50, the differences compared to those over 75 are particularly noteworthy with respect to concerns about changes in diet, visible changes from surgery, and financial issues. The salience of financial issues is also high for individuals under 65. Factors that are likely driving these changes include the impact of bowel dysfunction on daily life when working outside the home, as well as lack of Medicare insurance, and loss of wages among younger survivors.

Two findings warrant further discussion. First, individuals who reported not having graduated from high school were significantly less likely to state that body function changes were a survivorship priority (30.6%) when compared to other groups with increasing levels of education (41.2%, 44.4%, 45.6% and 41.4%). This may be due to differences in expectations, priorities and resources by educational status, or the vague wording of the response category "changes to body function." Second, patients diagnosed with stage 0

disease reported relatively high unmet needs relating to treatment options (19%) and side effects (20.6%). Adjusted analyses showed these rates did not significantly differ in comparison to stage 1 patients (15.2% and 18.5%, respectively) whose care is more complex. This may be explained by the fact that stage 0 patients, who may be treated solely by removal of a small cancer in a polyp during a colonoscopy, receive relatively little information about their cancer, recurrence risk, and follow-up care in comparison to those who see a surgeon or oncologist in addition to a gastroenterologist.

Because potential survey participants were identified through the PORTAL infrastructure, we were able to recruit a population-based random sample of survivors and we were able to link responses to clinical and demographic data. The results of this multi-center study have broad generalizability to recent U.S. CRC survivors with health insurance. They may not extend to those without insurance, or to disadvantaged groups, among whom our response rates were quite low[9]. Particularly among those under age 65, further research is warranted to explore priorities and unmet needs among survivors who are under-insured, uninsured, or who receive care outside of integrated delivery systems. We did not collect data that could have helped to determine whether unmet needs and survivorship concerns are influenced by educational interventions, type of insurance coverage, or incidence of treatment-related complications. These are opportunities for further research.

Our main goal was to identify subgroup differences in priorities and concerns. Survivors who could most benefit from care improvement and survivorship interventions include: rectal cancer survivors, individuals of racial-ethnic minority background, and younger survivors (particularly under 65). Individuals with later stage disease and those with lower educational attainment could also benefit. Further research should seek to identify interventions that reduce these quality gaps in high risk groups.

## Acknowledgements:

This study used the infrastructure developed by the PORTAL (Patient Outcomes Research to Advance Learning) Network, a consortium of three integrated delivery systems (Kaiser Permanente, HealthPartners, and Denver Health) and their affiliated research centers. Research reported in this article was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (CDRN-1306-04681 Phase II). The PORTAL infrastructure builds upon data structures that receive ongoing support from the National Cancer Institute Cancer (NCI) Research Network (Grant No. U24 CA171524, awarded to Dr. Lawrence H. Kushi, PI) and the Kaiser Permanente Center for Effectiveness and Safety Research. The statements in this article are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee.


**Funding:** This work was supported by Contract No. CDRN-1306-04681 from the Patient Outcomes Research Institute (Awarded to Drs. Elizabeth M. McGlynn and Tracy Lieu). The work builds upon data structures that receive ongoing support from the National Cancer Institute Cancer (NCI) Research Network (Grant No. U24 CA171524, awarded to Dr. Lawrence H Kushi, PI) and the Kaiser Permanente Center for Effectiveness and Safety Research.

## References:

1. Black N (2013) Patient reported outcome measures could help transform healthcare. *Bmj* 346:f167. doi:10.1136/bmj.f167 [PubMed: 23358487]
2. Institute of Medicine, National Research Council (2006) *From Cancer Patient to Cancer Survivor: Lost in Transition*. The National Academies Press, Washington, DC. doi:doi:10.17226/11468



3. Beckjord EB, Arora NK, McLaughlin W, Oakley-Girvan I, Hamilton AS, Hesse BW (2008) Health-related information needs in a large and diverse sample of adult cancer survivors: implications for cancer care. *J Cancer Surviv* 2 (3):179–189. doi:10.1007/s11764-008-0055-0 [PubMed: 18792791]
4. Kent EE, Arora NK, Rowland JH, Bellizzi KM, Forsythe LP, Hamilton AS, Oakley-Girvan I, Beckjord EB, Aziz NM (2012) Health information needs and health-related quality of life in a diverse population of long-term cancer survivors. *Patient Educ Couns* 89 (2):345–352. doi:10.1016/j.pec.2012.08.014 [PubMed: 23021856]
5. Burg MA, Adorno G, Lopez ED, Loerzel V, Stein K, Wallace C, Sharma DK (2015) Current unmet needs of cancer survivors: Analysis of open-ended responses to the American Cancer Society Study of Cancer Survivors II. *Cancer* 121 (4):623–630. doi:10.1002/cncr.28951 [PubMed: 25581252]
6. Corner J, Wagland R, Glaser A, Richards SM (2013) Qualitative analysis of patients' feedback from a PROMs survey of cancer patients in England. *BMJ open* 3 (4). doi:10.1136/bmjopen-2012-002316
7. Corley DA, Feigelson HS, Lieu TA, McGlynn EA (2015) Building Data Infrastructure to Evaluate and Improve Quality: PCORnet. *Journal of oncology practice* 11 (3):204–206. doi:10.1200/jop.2014.003194 [PubMed: 25980016]
8. McGlynn EA, Lieu TA, Durham ML, Bauck A, Laws R, Go AS, Chen J, Feigelson HS, Corley DA, Young DR, Nelson AF, Davidson AJ, Morales LS, Kahn MG (2014) Developing a data infrastructure for a learning health system: the PORTAL network. *J Am Med Inform Assoc* 21 (4): 596–601. doi:10.1136/amiajnl-2014-002746 [PubMed: 24821738]
9. Feigelson HS, McMullen CK, Madrid S, Sterrett AT, Powers JD, Blum-Barnett E, Pawloski PA, Ziegenfuss JY, Quinn VP, Arterburn DE, Corley DA (2017) Optimizing patient-reported outcome and risk factor reporting from cancer survivors: a randomized trial of four different survey methods among colorectal cancer survivors. *J Cancer Surviv* 11 (3):393–400. doi:10.1007/s11764-017-0596-1 [PubMed: 28084606]
10. Wagner EH, Greene SM, Hart G, Field TS, Fletcher S, Geiger AM, Herrinton LJ, Hornbrook MC, Johnson CC, Mouchawar J, Rolnick SJ, Stevens VJ, Taplin SH, Tolsma D, Vogt TM (2005) Building a research consortium of large health systems: the Cancer Research Network. *J Natl Cancer Inst Monogr* (35):3–11. doi:10.1093/jncimonographs/lgi032 [PubMed: 16287880]
11. Ritzwoller DP, Carroll N, Delate T, O'Keeffe-Rossetti M, Fishman PA, Loggers ET, Aiello Bowles EJ, Elston-Lafata J, Hornbrook MC (2013) Validation of electronic data on chemotherapy and hormone therapy use in HMOs. *Med Care* 51 (10):e67–73. doi:10.1097/MLR.0b013e31824def85 [PubMed: 22531648]
12. Ross TR, Ng D, Brown JS, Pardee R, Hornbrook MC, Hart G, Steiner JF (2014) The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration. *EGEMS (Washington, DC)* 2 (1):1049. doi:10.13063/2327-9214.1049
13. Hornbrook MC, Hart G, Ellis JL, Bachman DJ, Ansell G, Greene SM, Wagner EH, Pardee R, Schmidt MM, Geiger A, Butani AL, Field T, Fouayzi H, Miroshnik I, Liu L, Diseker R, Wells K, Krajenta R, Lamerato L, Neslund Dudas C (2005) Building a virtual cancer research organization. *J Natl Cancer Inst Monogr* (35):12–25. doi:10.1093/jncimonographs/lgi033
14. Naylor K, Ward J, Polite BN (2012) Interventions to improve care related to colorectal cancer among racial and ethnic minorities: a systematic review. *J Gen Intern Med* 27 (8):1033–1046. doi: 10.1007/s11606-012-2044-2 [PubMed: 22798214]
15. Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, Ozakinci G (2013) Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. *J Cancer Surviv* 7 (3):300–322. doi:10.1007/s11764-013-0272-z [PubMed: 23475398]
16. McMullen CK, Bulkley JE, Altschuler A, Wendel CS, Grant M, Hornbrook MC, Sun V, Krouse RS (2016) Greatest Challenges of Rectal Cancer Survivors: Results of a Population-Based Survey. *Dis Colon Rectum* 59 (11):1019–1027. doi:10.1097/dcr.0000000000000695 [PubMed: 27749476]



**Figure 1.** Adjusted mean number of unmet health care needs by demographic and clinical characteristics (N=1,825)

**Table 1.**

Characteristics of survey respondents, by cancer site

Characteristics	Cancer Site				p-value
	Overall (N=1947)	Colon (N=1418)	Rectosigmoid (N=101)	Rectal (N=428)	
<i>Demographic characteristics</i>					
Age at survey, in years					
<50	124 (6.4%)	79 (5.6%)	4 (4.0%)	41 (9.6%)	<0.001
50–64	589 (30.3%)	370 (26.1%)	45 (45.6%)	174 (40.7%)	
65–74	611 (31.4%)	437 (30.8%)	31 (30.7%)	143 (33.4%)	
75	623 (32.0%)	532 (37.5%)	21 (20.8%)	70 (16.4%)	
Male	995 (51.1%)	689 (48.6%)	44 (43.6%)	262 (61.2%)	<0.001
Race/Ethnicity					
Hispanic (any race)	267 (13.7%)	179 (12.6%)	17 (16.8%)	71 (16.6%)	0.07
White (non-Hispanic)	1345 (69.1%)	984 (69.4%)	69 (68.3%)	292 (68.2%)	
Black (non-Hispanic)	149 (7.7%)	122 (8.6%)	3 (3.0%)	24 (5.6%)	
Asian (non-Hispanic)	170 (8.7%)	122 (8.6%)	8 (7.9%)	40 (9.4%)	
Multiple / Other / Unknown	16 (0.8%)	11 (0.78%)	4 (4.0%)	1 (0.23%)	
Highest level of education					
Some high school	170 (8.7%)	119 (8.4%)	14 (13.9%)	37 (8.6%)	0.34
High school graduate or GED	345 (17.7%)	255 (18.0%)	19 (18.8%)	71 (16.6%)	
Some college or 2-year degree	657 (33.7%)	469 (33.1%)	34 (33.7%)	154 (36.0%)	
College graduate	305 (15.7%)	232 (16.4%)	8 (7.9%)	65 (15.2%)	
More than a college degree	384 (19.7%)	281 (19.8%)	19 (18.8%)	84 (19.6%)	
<i>Clinical characteristics</i>					
Years since diagnosis, mean (SD)	3.3 (1.11)	3.3 (1.1)	3.3 (1.1)	3.3 (1.1)	0.96
Years since surgery, mean (SD)	3.2 (1.12)	3.3 (1.1)	3.2 (1.1)	3.2 (1.2)	0.51
Stage at diagnosis					
0	194 (10.0%)	130 (9.2%)	9 (8.9%)	55 (12.9%)	0.13
1	631 (32.4%)	456 (32.2%)	37 (36.6%)	138 (32.2%)	
2	509 (26.1%)	397 (28.0%)	20 (19.8%)	92 (21.5%)	
3	506 (26.0%)	357 (25.2%)	28 (27.7%)	121 (28.3%)	
4	86 (4.4%)	64 (4.5%)	6 (5.9%)	16 (3.7%)	
Unknown	21 (1.1%)	14 (1%)	1 (1%)	6 (1.4%)	
Received chemotherapy (%)	716 (36.8%)	430 (30.3%)	44 (43.6%)	242 (56.5%)	<0.001
Received radiotherapy (%)	151 (7.8%)	4 (.28%)	13 (12.9%)	134 (31.3%)	<0.001

**Table 2:**

Number and proportion of reported unmet needs relating to cancer care experience (n=1947)

	Treatment options	Side effects	Recovery time	Life after treatment
Age at survey, in years				
<50	26 (20.0%)	36 (29.0%)	23 (18.6%)	40 (32.3%)
50–64	128 (21.7%)	168 (28.5%)	148 (25.1%)	203 (34.5%)
65–74	111 (18.2%)	144 (23.6%)	114 (18.7%)	153 (25.0%)
75	94 (15.1%)	113 (18.1%)	97 (15.6%)	124 (19.9%)
Gender				
Female	171 (18.0%)	227 (23.8%)	189 (19.9%)	261 (27.4%)
Male	188 (18.9%)	234 (23.5%)	193 (19.4%)	259 (26.0%)
Race/Ethnicity				
White, non-Hispanic	252 (15.7%)	364 (22.7%)	288 (17.9%)	401 (24.9%)
Other	105 (32.2%)	95 (29.1%)	89 (27.3%)	112 (34.3%)
Education				
Some high school	52 (30.6%)	58 (34.1%)	41 (24.1%)	51 (30.0%)
High school graduate	52 (15.1%)	68 (19.7%)	56 (16.2%)	81 (23.5%)
Some college	123 (18.7%)	151 (23.0%)	136 (20.7%)	190 (28.9%)
College graduate	61 (20.0%)	84 (27.5%)	62 (20.3%)	78 (25.6%)
Graduate school	59 (15.4%)	89 (23.2%)	76 (19.8%)	106 (27.6%)
Cancer site				
Colon	242 (17.1%)	295 (20.8%)	258 (18.2%)	338 (23.8%)
Rectosigmoid	19 (18.8%)	22.8 (23%)	15 (14.9%)	23 (22.8%)
Rectum	98 (22.9%)	143 (33.4%)	109 (25.5%)	159 (37.2%)
Stage at diagnosis				
0	37 (19.1%)	40 (20.6%)	30 (15.5%)	40 (20.6%)
1	96 (15.2%)	117 (18.5%)	121 (19.2%)	147 (23.3%)
2	85 (16.7%)	114 (22.4%)	99 (19.5%)	140 (27.5%)
3	112 (22.1%)	152 (30.0%)	104 (20.6%)	160 (31.6%)
4	24 (27.9%)	29 (33.7%)	24 (27.9%)	26 (30.2%)

**Table 3.** Multivariable logistic regression models predicting unmet needs relating to cancer care experience

Characteristic	Odds ratio (95% confidence interval) and p value		
	Better information or understanding about treatment options	Better information or understanding about treatment side effects	Better information or understanding about recovery time
<b>Age</b>			
<50	1.17 (0.68, 2.01) p=0.58	1.44 (0.89, 2.33) p=0.14	1.09 (0.64, 1.89) p=0.75
50-64	1.41 (1.02, 1.95) p=0.04	1.64 (1.22, 2.21) p<0.001	1.82 (1.33, 2.48) p<0.001
65-74	1.17 (0.84, 1.62) p=0.35	1.37 (1.02, 1.84) p=0.04	1.19 (0.87, 1.63) p=0.29
75	- ref -	- ref -	- ref -
<b>Gender</b>			
Female	0.90 (0.71, 1.16) p=0.42	1.05 (0.84, 1.32) p=0.67	1.01 (0.80, 1.28) p=0.94
Male	- ref -	- ref -	- ref -
<b>Race/Ethnicity</b>			
Minority race/ethnicity	2.66 (1.99, 3.55) p<0.001	1.44 (1.09, 1.92) p=0.01	1.79 (1.34, 2.39) p<0.001
White and/or Non-Hispanic	- ref -	- ref -	- ref -
<b>Education</b>			
Some high school but did not graduate	- ref -	- ref -	- ref -
High school graduate or GED	0.38 (0.24, 0.61) p<0.001	0.46 (0.30, 0.71) p<0.001	0.61 (0.39, 0.98) p=0.039
Some college or 2 year degree	0.48 (0.33, 0.72) p<0.001	0.55 (0.38, 0.81) p<0.001	0.75 (0.50, 1.13) p=0.17
College graduate	0.46 (0.30, 0.73) p<0.001	0.67 (0.44, 1.02) p=0.06	0.70 (0.44, 1.11) p=0.13
More than a college degree	0.38 (0.24, 0.59) p<0.001	0.55 (0.37, 0.84) p=0.005	0.72 (0.46, 1.13) p=0.16
<b>Cancer site</b>			
Rectosigmoid	1.18 (0.67, 2.06) p=0.57	1.13 (0.67, 1.88) p=0.65	0.72 (0.40, 1.32) p=0.29
Rectal	1.43 (1.07, 1.91) p=0.02	1.85 (1.43, 2.40) p<0.001	1.46 (1.11, 1.92) p=0.007
Colon	- ref -	- ref -	- ref -
<b>Stage at diagnosis</b>			
0	1.43 (.92, 2.22) p=0.11	1.24 (0.82, 1.88) p=0.32	0.8 (0.51, 1.26) p=0.33
1	- ref -	- ref -	- ref -
2	1.23 (0.88, 1.72) p=0.23	1.41 (1.04, 1.91) p=0.03	1.12 (0.82, 1.52) p=0.47
			Better information or understanding about life after treatment
			1.63 (1.03, 2.60) p=0.04
			2.03 (1.53, 2.69) p<0.001
			1.26 (0.95, 1.68) p=0.11
			- ref -
			1.07 (0.86, 1.33) p=0.55
			- ref -
			1.63 (1.24, 2.15) p<0.001
			- ref -
			- ref -
			0.71 (0.46, 1.08) p=0.11
			0.87 (0.59, 1.28) p=0.49
			0.70 (0.45, 1.08) p=0.11
			0.82 (0.54, 1.24) p=0.35
			0.80 (0.47, 1.36) p=0.41
			1.83 (1.43, 2.35) p<0.001
			- ref -
			0.89 (0.59, 1.34) p=0.56
			- ref -
			1.39 (1.05, 1.85) p=0.02

Characteristic	Odds ratio (95% confidence interval) and p value			
	Better information or understanding about treatment options	Better information or understanding about treatment side effects	Better information or understanding about recovery time	Better information or understanding about life after treatment
3	1.59 (1.16, 2.20) p=0.004	1.9 (1.42, 2.54) p<0.001	1.08 (0.80, 1.47) p=0.61	1.5 (1.14, 1.99) p=0.004
4	2.07 (1.18, 3.65) p=0.01	2.17 (1.29, 3.65) p=0.004	1.43 (0.82, 2.48) p=0.21	1.22 (0.71, 2.09) p=0.47

Note: All models are adjusted for health plan

**Table 4:** Number and proportion of reported health and lifestyle concerns (other than having cancer) (n=1947)

	Activity limitation	Sleep	Weight changes	Diet changes	Changes to body function	Visible changes from surgery	Financial issues	Cancer recurrence
Age at survey								
<50	40 (32%)	30 (24%)	47 (38%)	44 (36%)	49 (40%)	34 (27%)	30 (24%)	85 (69%)
50-64	164 (28%)	147 (25%)	141 (24%)	148 (25%)	281 (48%)	119 (20%)	114 (19%)	392 (66%)
65-74	155 (25%)	114 (19%)	136 (23%)	108 (18%)	241 (39%)	100 (16%)	77 (13%)	349 (57%)
75	162 (26%)	123 (20%)	144 (23%)	102 (16%)	226 (36%)	70 (11%)	44 (7%)	320 (51%)
Gender								
Female	254 (27%)	219 (23%)	268 (28%)	205 (22%)	376 (40%)	162 (17%)	137 (14%)	562 (59%)
Male	267 (27%)	195 (20%)	200 (20%)	197 (20%)	421 (42%)	161 (16%)	128 (13%)	584 (59%)
Race/Ethnicity								
Non-Hispanic White	427 (27%)	332 (21%)	377 (24%)	316 (20%)	659 (41%)	258 (16%)	198 (12%)	956 (60%)
Other	91 (28%)	79 (24%)	88 (27%)	84 (26%)	132 (41%)	65 (20%)	65 (20%)	181 (55%)
Education								
Some high school	58 (34%)	38 (22%)	40 (23%)	44 (26%)	52 (31%)	36 (21%)	27 (16%)	97 (57%)
High school graduate	87 (25%)	70 (20%)	91 (26%)	69 (20%)	142 (41%)	67 (19%)	50 (14%)	200 (58%)
Some college	185 (28%)	169 (26%)	177 (27%)	147 (22%)	292 (44%)	121 (18%)	108 (16%)	431 (66%)
College graduate	87 (28%)	68 (23%)	73 (24%)	61 (20%)	139 (46%)	47 (15%)	30 (10%)	180 (60%)
Graduate school	98 (25%)	60 (15%)	75 (19%)	75 (19%)	159 (41%)	48 (12%)	44 (11%)	217 (56%)
Cancer site								
Colon	342 (24%)	308 (22%)	347 (24%)	274 (19%)	505 (36%)	182 (13%)	180 (13%)	842 (59%)
Rectosigmoid	21 (21%)	13 (13%)	16 (16%)	22 (22%)	53 (52%)	14 (14%)	17 (17%)	56 (55%)
Rectum	158 (37%)	93 (22%)	105 (24%)	106 (25%)	239 (56%)	127 (30%)	68 (16%)	248 (58%)
Stage at diagnosis								
0	35 (18%)	34 (17%)	43 (22%)	28 (14%)	53 (27%)	19 (10%)	18 (9%)	107 (55%)
1	140 (22%)	118 (19%)	141 (22%)	123 (19%)	260 (41%)	93 (15%)	75 (12%)	360 (57%)
2	136 (27%)	111 (22%)	128 (25%)	109 (21%)	237 (47%)	100 (20%)	55 (11%)	288 (57%)
3	165 (32%)	114 (22%)	128 (25%)	116 (23%)	207 (41%)	85 (17%)	86 (17%)	329 (65%)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

4	Activity limitation	Sleep	Weight changes	Diet changes	Changes to body function	Visible changes from surgery	Financial issues	Cancer recurrence
	39 (45%)	32 (37%)	24 (28%)	20 (23%)	32 (37%)	21 (24%)	28 (33%)	52 (60%)



**Table 5.** Multivariable logistic regression models predicting endorsement of health and lifestyle concerns

Characteristic	Odds ratio (95% confidence interval) and p value							
	Limitations on activity	Inability to sleep or lack of sleep	Changes to weight	Changes to diet	Changes to my body functions	Changes from surgery that I can see	Financial issues	Possibility of cancer recurrence
<b>Age</b>								
<50	1.04 (0.66, 1.63) p=0.88	1.35 (0.83, 2.20) p=0.23	2.40 (1.55, 3.73) p<0.001	2.95 (1.86, 4.66) p<0.001	1.06 (0.69, 1.64) p=0.78	3.12 (1.88, 5.18) p<0.001	4.36 (2.51, 7.57) p<0.001	2.42 (1.53, 3.83) p<0.001
50-64	0.97 (0.74, 1.28) p=0.83	1.43 (1.07, 1.92) p=0.02	1.10 (0.83, 1.47) p=0.51	1.76 (1.30, 2.38) p<0.001	1.54 (1.20, 1.99) p<0.001	1.87 (1.32, 2.65) p<0.001	3.13 (2.11, 4.65) p<0.001	2.19 (1.70, 2.84) p<0.001
65-74	0.91 (0.69, 1.20) p=0.50	0.97 (0.72, 1.30) p=0.82	1.00 (0.76, 1.33) p=0.97	1.08 (0.79, 1.48) p=0.62	1.08 (0.84, 1.39) p=0.53	1.50 (1.06, 2.13) p=0.02	1.84 (1.22, 2.77) p=0.004	1.31 (1.03, 1.67) p=0.03
75	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-
<b>Gender</b>								
Female	1.00 (0.81, 1.23) p=0.98	1.18 (0.94, 1.49) p=0.15	1.53 (1.22, 1.90) p<0.001	1.09 (0.86, 1.37) p=0.48	0.90 (0.74, 1.09) p=0.29	1.13 (0.87, 1.46) p=0.36	1.04 (0.79, 1.38) p=0.77	0.93 (0.76, 1.13) p=0.45
Male	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-
<b>Race/Ethnicity</b>								
Minority race/ethnicity	1.13 (0.85, 1.50) p=0.40	1.21 (0.90, 1.62) p=0.22	1.14 (0.86, 1.52) p=0.37	1.42 (1.06, 1.91) p=0.02	1.01 (0.78, 1.31) p=0.95	1.36 (0.98, 1.88) p=0.07	1.85 (1.33, 2.58) p<0.001	0.78 (0.60, 1.01) p=0.06
White and/or Non-Hispanic	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-
<b>Education</b>								
Some high school	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-
High school graduate or GED	0.65 (0.43, 0.99) p=0.04	0.87 (0.55, 1.37) p=0.55	1.13 (0.73, 1.75) p=0.59	0.79 (0.51, 1.24) p=0.31	1.78 (1.18, 2.68) p=0.006	0.90 (0.56, 1.45) p=0.65	0.90 (0.53, 1.54) p=0.71	1.07 (0.73, 1.58) p=0.72
Some college or 2 year degree	0.74 (0.51, 1.07) p=0.11	1.14 (0.76, 1.72) p=0.54	1.15 (0.76, 1.71) p=0.51	0.82 (0.55, 1.22) p=0.32	1.89 (1.30, 2.76) p<0.001	0.78 (0.50, 1.21) p=0.26	0.95 (0.58, 1.53) p=0.82	1.35 (0.95, 1.93) p=0.09

Characteristic	Odds ratio (95% confidence interval) and p value								Possibility of cancer recurrence
	Limitations on activity	Inability to sleep or lack of sleep	Changes to weight	Changes to diet	Changes to my body functions	Changes from surgery that I can see	Financial issues		
College graduate	0.75 (0.49, 1.13) p=0.17	0.91 (0.57, 1.44) p=0.68	0.97 (0.61, 1.52) p=0.88	0.67 (0.42, 1.05) p=0.08	2.09 (1.38, 3.17) p<0.001	0.63 (0.38, 1.04) p=0.07	0.45 (0.25, 0.81) p=0.008	1.03 (0.69, 1.52) p=0.90	
More than a college degree	0.65 (0.43, 0.97) p=0.04	0.62 (0.39, 0.98) p=0.04	0.74 (0.47, 1.15) p=0.18	0.72 (0.47, 1.13) p=0.15	1.69 (1.13, 2.53) p=0.01	0.48 (0.29, 0.79) p=0.004	0.58 (0.34, 1.01) p=0.05	0.92 (0.63, 1.34) p=0.66	
<b>Cancer site</b>									
Colon	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-	
Rectosigmoid	0.82 (0.48, 1.38) p=0.45	0.47 (0.25, 0.89) p=0.021	0.63 (0.36, 1.10) p=0.11	1.19 (0.71, 1.98) p=0.52	2.47 (1.58, 3.88) p<0.001	1.10 (0.60, 2.01) p=0.76	1.18 (0.65, 2.13) p=0.59	0.72 (0.46, 1.13) p=0.16	
Rectal	1.96 (1.53, 2.51) p<0.001	0.95 (0.72, 1.26) p=0.71	1.01 (0.77, 1.33) p=0.92	1.19 (0.91, 1.58) p=0.21	2.36 (1.86, 2.99) p<0.001	2.78 (2.10, 3.68) p<0.001	1.05 (0.75, 1.46) p=0.78	0.78 (0.61, 0.99) p=0.04	
<b>Cancer stage</b>									
0	0.78 (0.51, 1.19) p=0.25	1.02 (0.66, 1.57) p=0.93	1.09 (0.73, 1.63) p=0.69	0.72 (0.46, 1.15) p=0.17	0.57 (0.39, 0.82) p=0.003	0.60 (0.35, 1.03) p=0.07	0.84 (0.48, 1.47) p=0.54	1.09 (0.77, 1.56) p=0.62	
1	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-	-ref-	
2	1.30 (0.98, 1.71) p=0.070	1.22 (0.90, 1.64) p=0.20	1.20 (0.90, 1.59) p=0.22	1.21 (0.90, 1.63) p=0.21	1.38 (1.07, 1.77) p=0.01	1.57 (1.13, 2.18) p=0.007	1.00 (0.68, 1.47) p=1.0	1.00 (0.78, 1.28) p=0.97	
3	1.66 (1.26, 2.19) p<0.001	1.17 (0.86, 1.57) p=0.32	1.08 (0.81, 1.44) p=0.60	1.09 (0.81, 1.48) p=0.56	0.96 (0.75, 1.24) p=0.76	1.07 (0.77, 1.51) p=0.68	1.43 (1.01, 2.04) p=0.05	1.36 (1.05, 1.76) p=0.02	
4	2.70 (1.66, 4.41) p<0.001	2.23 (1.34, 3.73) p=0.002	1.04 (0.60, 1.80) p=0.88	1.05 (0.60, 1.85) p=0.87	0.78 (0.47, 1.28) p=0.33	1.52 (0.84, 2.73) p=0.16	3.29 (1.90, 5.72) p<0.001	1.05 (0.64, 1.71) p=0.86	

Note: All models are adjusted for health plan